Margherita Bodini

TL;DR: In this paper, the authors examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine, and found that it was possible to predict strain coverage in four out of five cases, without requiring a cultivable isolate.

TL;DR: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture confirmed cases as discussed by the authors.

TL;DR: It is necessary to select patients with a history of atypical central giant cell granuloma, particularly if they have a family history of the disease, and select patients who are likely to be at high-risk of developing mantle cell lymphoma.

TL;DR: The findings raise the possibility that landscapes of AML genomes might be more complex than previously reported and characterized by the presence of hundreds of genes mutated at low variant allele frequency, suggesting that the application of genome sequencing to the clinic requires a careful and critical evaluation.

TL;DR: In this paper, a series of argumentations supporting the hypothesis that invasive meningococcal disease comes as a result of the coexistence of bacterial virulence and variability factors in a plot that can be further complicated by additional latent factors, like host pre-existing immune status and genetic predisposition.